Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forma Therapeutics, a biopharmaceutical company, has signed a collaboration agreement with Cubist Pharmaceuticals to leverage Forma's transformative chemistry platform to discover novel antibacterial compounds for development by Cubist.
Subscribe to our email newsletter
Forma will receive an upfront payment, equity investment, payments for compounds delivered and research funding over the three-year collaboration term totaling up to $14 million and is eligible to receive up to an additional $54 million in milestones plus royalties on programs that Cubist elects to move into development and commercialization.
Steven Tregay, CEO of Forma, said: “Working collaboratively with Cubist will allow us to demonstrate the power of Forma’s unique discovery platform to address the urgent need for new chemical matter in the field of antibacterial research.”